Loading
A phase 2 trial of gemcitabine, oxaliplatin and lenvatinib in gallbladder cancer and other biliary tract cancers, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.
Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer is a phase 2 interventional study registered as NCT07263360 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 29 participants, started 2026-02-01 and due to reach its primary completion in 2028-03-31. Interventions recorded: Iparomlimab and Tuvonralimab Injection combined with GemOX and lenvatinib. Conditions listed: BTC. Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lenvatinib, Intrahepatic cholangiocarcinoma, Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
Shares Lenvatinib, Intrahepatic cholangiocarcinoma, Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
Shares Lenvatinib, Intrahepatic cholangiocarcinoma, Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
Shares Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Intrahepatic cholangiocarcinoma, Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine and the tag gallbladder-deep-dive.
Shares Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Lenvatinib, Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine and the tag gallbladder-deep-dive.
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/